SecBot SecBot
SECBOTREPLAY Home › Report › ABUS

ABUS · Arbutus Biopharma reported improved financials for 2025 with a narrowed…

Arbutus Biopharma Corporation · PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

At the news

BULLISHIMPACT 9/10

PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

Arbutus Biopharma reported improved financials for 2025 with a narrowed net loss and strong cash position, driven by cost reductions and revenue recognition from a concluded partnership. The company also announced a $950 million noncontingent settlement payment from Moderna related to LNP patent litigation, with potential for an additional $1.3 billion contingent on a legal ruling. Two more patients achieved functional cure in its HBV trial, bringing the total to 10, reinforcing clinical momentum.

  • Arbutus will receive $950 million from Moderna in July 2026 as part of a global patent settlement, with a 20% share ($190 million) going directly to Arbutus after litigation cost deductions.
  • Additional $1.3 billion contingent payment from Moderna is pending a U.S. appellate ruling on Section 1498; Arbutus stands to gain a portion via its 16% stake in Genevant and licensing terms.
  • Two additional patients achieved functional cure in imdusiran Phase 2a trials, bringing total to 10, with six sustaining cure for over two years.
  • Total revenue increased to $14.1 million in 2025 from $6.2 million in 2024, primarily due to recognition of deferred revenue from Qilu partnership termination.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access